Impact of autofluorescence for detection of parathyroid glands during thyroidectomy on postoperative parathyroid hormone levels: parallel multicentre randomized clinical trial.
Journal
The British journal of surgery
ISSN: 1365-2168
Titre abrégé: Br J Surg
Pays: England
ID NLM: 0372553
Informations de publication
Date de publication:
09 11 2023
09 11 2023
Historique:
received:
09
05
2023
revised:
20
06
2023
accepted:
08
08
2023
medline:
13
11
2023
pubmed:
28
9
2023
entrez:
27
9
2023
Statut:
ppublish
Résumé
Techniques for autofluorescence have been introduced to visualize the parathyroid glands during surgery and to reduce hypoparathyroidism after thyroidectomy. This parallel multicentre RCT investigated the use of Fluobeam® LX to visualize the parathyroid glands by autofluorescence during total thyroidectomy compared with no use. There was no restriction on the indication for surgery. Patients were randomized 1 : 1 and were blinded to the group allocation. The hypothesis was that autofluorescence enables identification and protection of the parathyroid glands during thyroidectomy. The primary endpoint was the rate of low parathyroid hormone (PTH) levels the day after surgery. Some 535 patients were randomized, and 486 patients received an intervention according to the study protocol, 246 in the Fluobeam® LX group and 240 in the control group. Some 64 patients (26.0 per cent) in the Fluobeam® LX group and 77 (32.1 per cent) in the control group had low levels of PTH after thyroidectomy (P = 0.141; relative risk (RR) 0.81, 95 per cent c.i. 0.61 to 1.07). Subanalysis of 174 patients undergoing central lymph node clearance showed that 15 of 82 (18 per cent) in the Fluobeam® LX group and 31 of 92 (33 per cent) in the control group had low levels of PTH on postoperative day 1 (P = 0.021; RR 0.54, 0.31 to 0.93). More parathyroid glands were identified during operation in patients who had surgery with Fluobeam® LX, and fewer parathyroid glands in the surgical specimen on definitive histopathology. No specific harm related to the use of Fluobeam® LX was reported. The use of autofluorescence during thyroidectomy did not reduce the rate of low PTH levels on postoperative day 1 in the whole group of patients. It did, however, reduce the rate in a subgroup of patients. Registration number: NCT04509011 (http://www.clinicaltrials.gov).
Sections du résumé
BACKGROUND
Techniques for autofluorescence have been introduced to visualize the parathyroid glands during surgery and to reduce hypoparathyroidism after thyroidectomy.
METHODS
This parallel multicentre RCT investigated the use of Fluobeam® LX to visualize the parathyroid glands by autofluorescence during total thyroidectomy compared with no use. There was no restriction on the indication for surgery. Patients were randomized 1 : 1 and were blinded to the group allocation. The hypothesis was that autofluorescence enables identification and protection of the parathyroid glands during thyroidectomy. The primary endpoint was the rate of low parathyroid hormone (PTH) levels the day after surgery.
RESULTS
Some 535 patients were randomized, and 486 patients received an intervention according to the study protocol, 246 in the Fluobeam® LX group and 240 in the control group. Some 64 patients (26.0 per cent) in the Fluobeam® LX group and 77 (32.1 per cent) in the control group had low levels of PTH after thyroidectomy (P = 0.141; relative risk (RR) 0.81, 95 per cent c.i. 0.61 to 1.07). Subanalysis of 174 patients undergoing central lymph node clearance showed that 15 of 82 (18 per cent) in the Fluobeam® LX group and 31 of 92 (33 per cent) in the control group had low levels of PTH on postoperative day 1 (P = 0.021; RR 0.54, 0.31 to 0.93). More parathyroid glands were identified during operation in patients who had surgery with Fluobeam® LX, and fewer parathyroid glands in the surgical specimen on definitive histopathology. No specific harm related to the use of Fluobeam® LX was reported.
CONCLUSION
The use of autofluorescence during thyroidectomy did not reduce the rate of low PTH levels on postoperative day 1 in the whole group of patients. It did, however, reduce the rate in a subgroup of patients. Registration number: NCT04509011 (http://www.clinicaltrials.gov).
Identifiants
pubmed: 37758507
pii: 7284300
doi: 10.1093/bjs/znad278
pmc: PMC10638529
doi:
Substances chimiques
Parathyroid Hormone
0
Banques de données
ClinicalTrials.gov
['NCT04509011']
Types de publication
Randomized Controlled Trial
Multicenter Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1824-1833Subventions
Organisme : Region Skåne
Informations de copyright
© The Author(s) 2023. Published by Oxford University Press on behalf of BJS Society Ltd.
Références
Langenbecks Arch Surg. 2008 Sep;393(5):667-73
pubmed: 18633639
World J Surg. 2021 Sep;45(9):2785-2790
pubmed: 33835219
Endocrine. 2019 Nov;66(2):405-415
pubmed: 31317524
Surgery. 2012 Dec;152(6):1059-67
pubmed: 23068088
Endocrine. 2021 May;72(2):546-552
pubmed: 33432503
Langenbecks Arch Surg. 2015 Apr;400(3):319-24
pubmed: 25749741
J Bone Miner Res. 2013 Dec;28(12):2570-6
pubmed: 23737456
Surgery. 2002 May;131(5):515-20
pubmed: 12019404
Ann Surg. 2021 Dec 1;274(6):e1202-e1208
pubmed: 32032086
Surgery. 2020 Jan;167(1):124-128
pubmed: 31570150
BJS Open. 2022 May 2;6(3):
pubmed: 35543262
Br J Surg. 2014 Mar;101(4):307-20
pubmed: 24402815
Langenbecks Arch Surg. 2022 Nov;407(7):3031-3038
pubmed: 35904639
Br J Surg. 2021 Jun 22;108(6):684-690
pubmed: 34157088
Front Endocrinol (Lausanne). 2022 Jun 16;13:897797
pubmed: 35784544
BJS Open. 2022 Sep 2;6(5):
pubmed: 36050906
J Surg Res. 2015 Aug;197(2):348-53
pubmed: 25982044
Eur Thyroid J. 2022 May 11;11(3):
pubmed: 35389883
Endocrine. 2021 Jul;73(1):1-7
pubmed: 33651345
Br J Surg. 2016 Apr;103(5):537-43
pubmed: 26864909
Ann R Coll Surg Engl. 2019 Sep;101(7):508-513
pubmed: 31305127
Surgery. 2023 Jan;173(1):124-131
pubmed: 36244813
JAMA Surg. 2020 Feb 1;155(2):106-112
pubmed: 31693081
Br J Surg. 2018 Sep;105(10):1313-1318
pubmed: 29663312
J Clin Endocrinol Metab. 2014 Dec;99(12):4574-80
pubmed: 25148235
World J Surg. 2012 Aug;36(8):1933-42
pubmed: 22476788
World J Surg. 2014 Oct;38(10):2613-20
pubmed: 24791907
Surgery. 2022 Jun;171(6):1526-1534
pubmed: 35164952
Endocrine. 2022 Oct;78(1):151-158
pubmed: 35913569
J Biomed Opt. 2011 Jun;16(6):067012
pubmed: 21721833
J Am Coll Surg. 2019 May;228(5):744-751
pubmed: 30710614
Br J Surg. 2018 Mar;105(4):350-357
pubmed: 29405252